ODAC to discuss GSK's Tykerb in combination with Herceptin
13:53 EDT 30 May 2012 | BioCentury
FDA's Oncologic Drugs Advisory Committee will meet on July 24 to discuss an sNDA for Tykerb lapatinib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). GSK is seeking approval for Tykerb in combination with Herceptin trastuzumab to treat metastatic, HER2..
Original Article: ODAC to discuss GSK's Tykerb in combination with Herceptin
More From BioPortfolio on "ODAC to discuss GSK's Tykerb in combination with Herceptin"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
